杨娇娇是课题组与河北医科大学联培的硕士研究生，祝贺。感谢主编和审稿人的认可，以及杨娇娇导师向柏教授的支持

Abstract:

The management of breast cancer remains clinically intractable, driven by its highly invasive behavior and limited susceptibility to conventional treatments. In this study, we engineered an innovative cyclodextrin-porphyrin co-assembled nanoplatform (CT NPs) to enable multimodal breast cancer therapy. By successfully encapsulating camptothecin (CPT) within this nanocarrier, the system (CTC NPs) achieves synergistic chemo-phototherapeutic efficacy through dual-modality action. The highly biocompatible cyclodextrin carrier significantly improved the physicochemical characteristics of CPT. In vivo studies revealed that CTC NPs effectively evaded clearance by the reticuloendothelial system, overcame the defect of premature drug leakage, and exhibited superior tumor targeting and infiltration capabilities. Under near-infrared laser irradiation, CTC NPs can simultaneously induce localized hyperthermia and produce reactive oxygen species (ROS), thereby achieving efficient tumor ablation. In 4T1 tumor-bearing mice, CTC NPs exhibited targeted, safe, and highly potent anti-tumor efficacy, significantly suppressing both primary tumor progression (tumor suppression rate > 95%) and metastatic dissemination. In summary, this integrated nanoplatform establishes a novel theranostic paradigm for synergistic chemo-phototherapy against triple-negative breast cancer (TNBC), achieving precise tumor ablation through NIR-triggered drug release and real-time imaging guidance.